Bavituximab

From WikiCover

Bavituximab is the first investigational agent in a new class of anti-phosphotidylserine (anti-PS) monoclonal antibodies that targets and binds to cellular components that are normally not present on the outside of cells, but that become exposed on certain virally infected cells and on the surface of enveloped viruses. It is thought that anti-PS agents help stimulate the body's immune defenses to destroy both the virus particles and the infected cells. In preclinical studies, anti-PS antibodies have demonstrated their ability to bind to a wide range of enveloped viruses, as well as showing promising activity in animal models of serious viral diseases. Bavituximab was well tolerated and showed encouraging signs of antiviral activity in Phase la and Phase lb trials in patients with chronic hepatitis C viral infection.

On August 7, 2007, Peregrine Pharmaceuticals announced that final data from its Phase Ib study of bavituximab in patients with chronic hepatitis C viral (HCV) infection has been accepted for an oral presentation at The Liver Meeting 2007, hosted by the American Association for the Study of Liver Diseases.